


Submission

[Home > Submission](#)

 You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/10/2019
Deadline Date	30/10/2019
Date Submitted	23/10/2019
Type	Performance In Delivering
NHS provider	Essex Partnership University NHS Foundation Trust

Showing records 1 to 1 of 1.

System generated fieldid	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Drop down options. Please indicate whether the trial has a fixed target (Number Agreed), range target (Range Agreed) or no target agreed or available (Not Available /Not Agreed)Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Drop down options. Indicate if a target date has been agreed.Target Date To Recruit Patients Agreed?	Format dd/mm/yyyy. Please show the date agreed to recruit patients. Leave blank if unavailable.Date Agreed to recruit target number of patients	Please report the total number of patients recruited at the agreed target date.Total Number Of Patients Recruited At The Agreed Target Date	Please only include records for commercial trials which have closed to recruitment within the reporting window. Format dd/mm/yyyy.Date That The Trial Closed To Recruitment	Please report the total number of patients recruited.Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Please use the free text comment box for more information about the trial. Character limit: 500Comments
40806	17/SC/0595	233484	Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis	Number Agreed	3	3	Date Agreed	30/05/2020	0	09/09/2019	0	Withdrawn By Sponsor	Primary outcome of the study was positive, indicating that pimavanserin was superior to placebo in delaying time to relapse of dementia-related psychosis. As a result, the study has stopped for positive efficacy.

Showing records 1 to 1 of 1.

Pages: 1